GHRP-2

Also known as: Pralmorelin, KP-102

**Mechanism of Action** GHRP-2 (Pralmorelin) is a synthetic hexapeptide that acts as a potent agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a). By binding to this receptor in the pituitary and hypothalamus, it stimulates the release of growth hormone (GH) from somatotroph cells, primarily via activation of the Gq/11-phospholipase C signaling pathway. Additionally, GHRP-2 enhances appetite through hypothalamic neuropeptide Y (NPY) and agouti-related peptide (AgRP) pathways, and transiently elevates cortisol and prolactin levels via downstream hypothalamic-pituitary-adrenal axis activation. **Key Research Findings** Clinical trials have demonstrated that GHRP-2 induces a robust, dose-dependent GH pulse, with peak serum GH levels occurring 15–30 minutes after subcutaneous or intravenous administration. Studies in GH-deficient adults and children show its efficacy in diagnosing GH secretory capacity, with comparable or superior sensitivity to insulin tolerance tests. Research also indicates that GHRP-2 increases food intake and body weight in cachectic patients, though its effects on cortisol and prolactin are transient and generally well-tolerated. Long-term safety data remain limited, and its potential for abuse in sports or anti-aging contexts is a concern due to unregulated GH elevation. **Clinical Relevance** GHRP-2 is approved in Japan and several other countries for diagnostic use in GH deficiency and as a therapeutic agent for growth disorders. Its clinical applications extend to managing cachexia and muscle wasting, though off-label use for performance enhancement is not supported by robust evidence. Ongoing trials are evaluating its role in metabolic disorders and age-related sarcopenia. For research purposes only — not medical advice.

Key data

Research & studies

Frequently asked questions

Related peptides